HSPA9 is also part of a 12-biomarker panel that predicted PCa aggressiveness (surgical Gleason and TNM stage) and lethal outcome robustly in both high- and low-Gleason areas, despite biopsy-sampling error [66]. Here, HSPA9 is linked to posterior cortical atrophy.